Medicated Skin Care in Turkey
Medicated skin care faces significant competition from the beauty and personal care industry as a number of products are regarded more as cosmetics than medicine, because of the problems they are designed to solve. Medicated skin care includes products that are bought by consumers as self-medication, rather than treatments for more severe dermatological problems such as eczema or allergies. Substitutes for products in this category are usually cosmetic products rather than medicines.
Euromonitor International's Medicated Skin Care in Turkey report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide,
Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Euromonitor International's Medicated Skin Care in Turkey report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Medicated Skin Care market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide,
Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
MEDICATED SKIN CARE IN TURKEY
Euromonitor International
April 2012
LIST OF CONTENTS AND TABLES
Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Medicated Skin Care by Category: Value 2006-2011
Table 2 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
Table 3 Medicated Skin Care Company Shares by Value 2007-2011
Table 4 Medicated Skin Care Brand Shares by Value 2008-2011
Table 5 Hair Loss Treatments Brand Shares by Value 2008-2011
Table 6 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
Table 7 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016
Abdi Ibrahim Ilaç Sanayi Ve Ticaret As in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 1 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Key Facts
Summary 2 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Operational Indicators
Company Background
Production
Summary 3 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Production Statistics 2011
Competitive Positioning
Summary 4 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Competitive Position 2011
Biota Laboratuvarlari in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 5 Biota Laboratuvarlari: Key Facts
Summary 6 Biota Laboratuvarlari: Operational Indicators
Company Background
Production
Summary 7 Biota Laboratuvarlari: Production Statistics 2011
Competitive Positioning
Summary 8 Biota Laboratuvarlari: Competitive Position 2011
Kurtsan Ilaclari As in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 9 Kurtsan Ilaclari AS: Key Facts
Summary 10 Kurtsan Ilaclari AS: Operational Indicators
Company Background
Production
Summary 11 Kurtsan Ilaclari AS: Production Statistics 2011
Competitive Positioning
Summary 12 Kurtsan Ilaclari AS: Competitive Position 2011
Executive Summary
Consumer Health Demonstrates Positive Growth in 2011
Long-awaited OTC Legislation Is Still To Be Introduced
Multinational Companies Lead
Chemists/pharmacies Is the Dominant Distribution Channel
Consumer Health Is To Register Growth Over the Forecast Period
Key Trends and Developments
Improved Economic Conditions Benefit the Consumer Health Industry
the Long-awaited OTC Legislation Is To Expand Consumer Health
Increasing Life Expectancy in the Turkish Population
Rapid Urbanisation in the Country Is A Significant Factor Behind Growth
Production of Generics by Local Companies Stimulates Growth
Market Indicators
Table 8 Consumer Expenditure on Health Goods and Medical Services 2006-2011
Table 9 Life Expectancy at Birth 2006-2011
Market Data
Table 10 Sales of Consumer Health by Category: Value 2006-2011
Table 11 Sales of Consumer Health by Category: % Value Growth 2006-2011
Table 12 Consumer Health Company Shares 2007-2011
Table 13 Consumer Health Brand Shares 2008-2011
Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
Table 16 Forecast Sales of Consumer Health by Category: Value 2011-2016
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 13 OTC - Switches 2009-2011
Definitions
Sources
Summary 14 Research Sources
Euromonitor International
April 2012
LIST OF CONTENTS AND TABLES
Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Medicated Skin Care by Category: Value 2006-2011
Table 2 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
Table 3 Medicated Skin Care Company Shares by Value 2007-2011
Table 4 Medicated Skin Care Brand Shares by Value 2008-2011
Table 5 Hair Loss Treatments Brand Shares by Value 2008-2011
Table 6 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
Table 7 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016
Abdi Ibrahim Ilaç Sanayi Ve Ticaret As in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 1 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Key Facts
Summary 2 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Operational Indicators
Company Background
Production
Summary 3 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Production Statistics 2011
Competitive Positioning
Summary 4 Abdi Ibrahim Ilaç Sanayi ve Ticaret AS: Competitive Position 2011
Biota Laboratuvarlari in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 5 Biota Laboratuvarlari: Key Facts
Summary 6 Biota Laboratuvarlari: Operational Indicators
Company Background
Production
Summary 7 Biota Laboratuvarlari: Production Statistics 2011
Competitive Positioning
Summary 8 Biota Laboratuvarlari: Competitive Position 2011
Kurtsan Ilaclari As in Consumer Health (turkey)
Strategic Direction
Key Facts
Summary 9 Kurtsan Ilaclari AS: Key Facts
Summary 10 Kurtsan Ilaclari AS: Operational Indicators
Company Background
Production
Summary 11 Kurtsan Ilaclari AS: Production Statistics 2011
Competitive Positioning
Summary 12 Kurtsan Ilaclari AS: Competitive Position 2011
Executive Summary
Consumer Health Demonstrates Positive Growth in 2011
Long-awaited OTC Legislation Is Still To Be Introduced
Multinational Companies Lead
Chemists/pharmacies Is the Dominant Distribution Channel
Consumer Health Is To Register Growth Over the Forecast Period
Key Trends and Developments
Improved Economic Conditions Benefit the Consumer Health Industry
the Long-awaited OTC Legislation Is To Expand Consumer Health
Increasing Life Expectancy in the Turkish Population
Rapid Urbanisation in the Country Is A Significant Factor Behind Growth
Production of Generics by Local Companies Stimulates Growth
Market Indicators
Table 8 Consumer Expenditure on Health Goods and Medical Services 2006-2011
Table 9 Life Expectancy at Birth 2006-2011
Market Data
Table 10 Sales of Consumer Health by Category: Value 2006-2011
Table 11 Sales of Consumer Health by Category: % Value Growth 2006-2011
Table 12 Consumer Health Company Shares 2007-2011
Table 13 Consumer Health Brand Shares 2008-2011
Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
Table 16 Forecast Sales of Consumer Health by Category: Value 2011-2016
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 13 OTC - Switches 2009-2011
Definitions
Sources
Summary 14 Research Sources
